Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

Summary

This is a phase II, Single-arm,Open-label Study evaluating the safety and efficacy of CT053PTSA in Advanced Solid Tumors With MET Exon 14 Skipping Mutations

Timeline

Start

2022-11-27

Primary completion

2024-09-09

Completion

2024-12-09

Drugs

Indications